Standard BioTools Inc [LAB] stock is trading at $1.09, up 6.86%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LAB shares have gain 0.93% over the last week, with a monthly amount glided 3.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Standard BioTools Inc [NASDAQ: LAB] stock has seen the most recent analyst activity on February 27, 2025, when KeyBanc Capital Markets downgraded its rating to a Sector Weight. Previously, TD Cowen started tracking the stock with Buy rating on April 16, 2024, and set its price target to $3.50. On April 04, 2024, Jefferies initiated with a Buy rating and assigned a price target of $3.25 on the stock. KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and suggested a price target of $4 on July 12, 2023.
Standard BioTools Inc [LAB] stock has fluctuated between $0.92 and $2.41 over the past year. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Standard BioTools Inc [NASDAQ: LAB] shares were valued at $1.09 at the most recent close of the market. An investor can expect a potential return of 198.17% based on the average LAB price forecast.
Analyzing the LAB fundamentals
Standard BioTools Inc [NASDAQ:LAB] reported sales of 169.69M for the trailing twelve months, which represents a drop of -10.42%. Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -0.82%, Pretax Profit Margin comes in at -0.78%, and Net Profit Margin reading is -0.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.28 and Total Capital is -0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0400 points at the first support level, and at 0.9900 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1300, and for the 2nd resistance point, it is at 1.1700.
Ratios To Look Out For
For context, Standard BioTools Inc’s Current Ratio is 6.12. Further, the Quick Ratio stands at 5.37, while the Cash Ratio is 2.68. Considering the valuation of this stock, the price to sales ratio is 2.44, the price to book ratio is 0.91.
Transactions by insiders
Recent insider trading involved Kim Hanjoon Alex, Chief Financial Officer, that happened on May 23 ’25 when 1428.0 shares were sold. SVP & Chief Business Officer, Mackay Sean completed a deal on May 23 ’25 to sell 13217.0 shares. Meanwhile, President & CEO Egholm Michael sold 5473.0 shares on May 23 ’25.
